A revolutionary new jab designed to prevent HIV is set to be rolled out across the NHS in England and Wales, offering significant hope towards the goal of eradicating the virus within five years. This groundbreaking injection, known as cabotegravir or CAB-LA, provides almost 100 per cent effectiveness in protecting individuals from contracting HIV. Following its approval by the National Institute for Health and Care Excellence (NICE), the jab will become available at sexual health clinics within months, marking a pivotal moment in the NHS's ambition to become the first health service globally to eliminate HIV transmission by 2030.

The mechanism of cabotegravir involves blocking a crucial enzyme that the HIV virus requires to replicate itself within the body. By preventing this multiplication, the jab effectively stops the virus from taking hold if an individual is exposed. Unlike the existing daily HIV-prevention tablets, known as PrEP (pre-exposure prophylaxis), this new therapy is administered as an injection every two months by a healthcare professional. It is specifically targeted for approximately 1,000 people annually who are unable to use oral PrEP, which could be due to medical conditions, difficulties swallowing tablets, or unstable living situations.

Helen Knight, director of medicines evaluation at NICE, underscored the importance of this development, stating, "HIV remains a serious public-health challenge, but we now have powerful tools to prevent new infections." She further elaborated that for the approximately 1,000 people in England who cannot take daily oral PrEP due to medical contraindications or other barriers, this injection offers an effective and vital option. Dr. Michael Brady, NHS England's National Adviser for LGBT+ Health, echoed this sentiment, calling the long-acting injection "a significant addition to our HIV prevention strategies," providing a powerful new option for at-risk individuals who cannot use oral PrEP tablets.

The approval has been hailed as "game-changing" by Health Secretary Wes Streeting, who expressed that for vulnerable people unable to use other HIV prevention methods, this treatment represents hope. He affirmed the significant progress being made on HIV, noting an eight per cent increase in PrEP use this year, and reiterated England's commitment to being the first country to end HIV transmissions by 2030, with this breakthrough treatment serving as another powerful tool in achieving that crucial goal.

The rollout of CAB-LA is supported by broader efforts, including a major expansion of HIV testing in A&E departments. Currently, 89 hospitals in high-prevalence areas are screening all patients undergoing blood tests, a scheme anticipated to identify nearly 1,900 new or previously missed cases each year. According to the UK Health Security Agency, over 111,000 people accessed PrEP in sexual-health clinics in England during 2024, representing a seven per cent increase from the preceding year.

Charities have also celebrated the new jab as a vital step towards addressing inequalities. Richard Angell, chief executive of the Terrence Higgins Trust, emphasized that "Injectable PrEP will be transformative for our HIV response," highlighting its high effectiveness and potential to reach individuals currently not accessing prevention. Cabotegravir is manufactured by ViiV Healthcare, a division of GSK, at its facility in Barnard Castle, County Durham. Julie Guest, ViiV Healthcare's UK general manager, noted that as the first and only long-acting PrEP option available in the UK, cabotegravir offers an alternative to help people stay protected.

While HIV attacks the immune system and can lead to life-threatening illness if left untreated, modern medicines have advanced to effectively suppress the virus, rendering it 'undetectable'. This means that the virus cannot be passed on, underscoring the importance of innovative prevention and treatment options like cabotegravir in the ongoing fight against HIV.